ERβ deletion has recently been reported to collaborate with p53 inactivation to induce early onset breast tumors in mice [37] suggesting that ERβ synergizes with wild-type p53 to elicit anti-tumor activities in breast cancer cells. The gene discussed is ESR2; the disease is breast cancer.